Mr Nim Arumainayagam is a Consultant Urological Surgeon and the current Clinical Lead (Clinical Director) of the Department of Urology at Ashford & St Peter’s Hospitals NHS Trust, based in Surrey and London. He grew up near Southampton, where he attended school and then graduated from the University of Nottingham Medical School. His basic surgical training was undertaken in London and Bristol, followed by an 18 month period of research at University College Hospital London (UCLH), with a thesis on the diagnostic role of multiparametric MRI in prostate cancer resulting in an MD(Res) higher degree. He was also involved in running the focal therapy trials (using HIFU and photodynamic therapy) at UCLH during this period.
His subsequent higher SpR urological surgery training in London (Imperial North West London rotation – St Mary’s Hospital, Royal Marsden Hospital, West Middlesex Hospital, Hillingdon Hospital, Watford General Hospital, Charing Cross Hospital and Northwick Park Hospital), included a year sub-specialty training in surgical treatments for kidney and ureteric stone disease at Charing Cross Hospital, London.
He has held a substantive NHS Consultant post at Ashford and St Peter’s Hospitals NHS Trust since April 2015. As well as being the Clinical Lead for Urology, he is the Foundation Year 2 Training Programme Director and the Lead Cancer Clinician for Ashford and St Peter’s Hospitals NHS Trust. He is also extensively involved in prostate cancer research with numerous publications, national and international presentations in this field. He is also the principal investigator on numerous prostate cancer trials including focal therapy trials for prostate cancer. Trials include INDEX, PRONOUNCE, CADMUS, CHRONOS and PROSPECT.
Nim (as he is known to his patients) aims to provide an approachable and collaborative approach towards the health and care of his patients, with a drive towards adopting modern treatments and knowledge to achieve the best outcome for his patients. His main interests are in PSA testing, multiparametric MRI diagnosis of prostate cancer and MRI and ultrasound fusion guided transperineal prostate biopsies, prostate cancer treatment, alongside the diagnosis and treatment of bladder and testicular cancer.
- Consultant Urological Surgeon and the current Clinical Lead (Clinical Director) of the Department of Urology at Ashford & St Peter’s Hospitals NHS Trust
- NHS Consultant, Ashford
- St Peter’s Hospitals NHS Trust
- Lead Cancer Clinician, Ashford and St Peter’s Hospitals NHS Trust.
- University of Nottingham Medical School
- University College Hospital London (UCLH)
- St Mary’s Hospital
- Royal Marsden Hospital
- West Middlesex Hospital
- Hillingdon Hospital
- Watford General Hospital
- Charing Cross Hospital
- Northwick Park Hospital
- Charing Cross Hospital
- EAU Prize for 2nd Best Abstract by a Resident at EAU 2010 Meeting - WST-11 Mediated VTP in Localised Prostate Cancer
- EAU Prize for best presentation in section (Extended oral podium presentation) 2011 - A negative multi-parametric MRI can rule out up to 97% of clinically significant prostate cancer
- SURG awarded USANZ Travel Fellowship 2013 - To attend USANZ trainee week November 2013 in Auckland
- Imperial College London Simpson Smith Travel Fellowship Award 2014 - Award used to undertake mini-fellowship at Rainbow Hospital, Agra, India to enhance knowledge and skills relating to PCNL surgery
- RSM Geoffrey Chisholm Communication Prize for Best Presentation 2018 (supervised and senior author for the trainee presenting) - Prostate Cancer Litigation in the UK
- PSA screening and prostate cancer diagnostics and management
- Screening for bladder and kidney cancer (investigation of blood in the urine)
- Kidney Stone disease
- Strong research interest in prostate cancer trials (INDEX, CADMUS, PRONOUNCE and CHRONOS trial Principal Investigator at Ashford and St Peters Hospitals NHS Trust)
- Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST-11 Vascular Targeted Photodynamic (VTP) therapy. Moore CM, Azzouzi AR, Barret E, Villers A, Muir G, Barber N, Trachtenberg J, Arumainayagam N, Gaillac B, Allen C, Schertz A, Emberton M. BJU International May 2014
- Multi-parametric MR Imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Arumainayagam N, Ahmed HU, Moore CM, Freeman A, Allen C, Sohaib A, Kirkham A, Emberton M. Radiology September 2013
- A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. Hu Y, Ahmed HU, Carter T, Arumainayagam N, Lecornet E, Barzell W, Freeman A, Nevoux P, Hawkes DJ, Villers A, Emberton M, Barratt DC. BJU International September 2012
- Characterising Clinically Significant Prostate Cancer Using Template Prostate Mapping Biopsy. Ahmed HU, Hu Y, Carter T, Arumainayagam N, Lecornet E, Freeman A, Hawkes D, Barratt D, Emberton M. Journal of Urology August 2011
- Introduction of an Enhanced Recovery Protocol for Radical Cystectomy. Arumainayagam N, McGrath J, Jefferson KP, Gillatt DA. BJU International March 2008.
- Fellow of the Royal College of Surgeons of England
- British Medical Association